Magnetic Resonance Imaging trials for Prostate cancer

All Magnetic Resonance Imaging trials · All Prostate cancer trials

Phase breakdown

Recruiting trials studying Magnetic Resonance Imaging for Prostate cancer

• 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
  NCT07219147 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
  NCT06389786 · Phase: Not applicable (e.g. observational or device study) · Ages: 30 Years to 85 Years · Sex: Male · 1 location
• Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer
  NCT06325046 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · 5 locations
• An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique
  NCT06865768 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
  NCT06788886 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
  NCT05806515 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 133 locations
• Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT06236139 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
  NCT06330805 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial
  NCT07276438 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · 1 location
• Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
  NCT06526299 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 3 locations
• Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer
  NCT06625034 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 2 locations
• Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
  NCT06499870 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer
  NCT06369610 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
  NCT06205316 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 6 locations
• Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
  NCT06378866 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 3 locations
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
  NCT06632977 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 108 locations
• Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
  NCT05946213 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 413 locations
• Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
  NCT06470243 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 174 locations
• Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
  NCT06931340 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 210 locations
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
  NCT03866382 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 581 locations
• Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance
  NCT06733350 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Male · 1 location
• Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy
  NCT07075705 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · 1 location
• Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
  NCT04423211 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 341 locations
• Using FAPI PET/MRI to Evaluate Prostate Cancer
  NCT06675357 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
  NCT05852041 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location

Common questions

How many trials study Magnetic Resonance Imaging for Prostate cancer?

25 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.